BACKGROUND: This study evaluated the usefulness of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose (FDG-PET) in monitoring the response to continuous arterial infusion chemotherapy (CAI) combined with external radiation therapy (ERT) for unresectable pancreatic carcinomas. METHODS: Ten patients with unresectable pancreatic cancer were enrolled in this study. Computed tomography (CT) and FDG-PET were done before and after CAI (5-fluorouracil [FU], 500 mg/body per day) combined with ERT (50.4 Gy total dose). Tumor regression was evaluated by standardized uptake value (SUV) with FDG-PET, tumor size on CT, and changes in blood levels of carbohydrate antigen (CA) 19-9. The three methods of evaluation were compared. RESULTS: The ten patients were classified in three categories. In category I, tumor changes evident on CT and FDG-PET were consistent. In category II, CT could not accurately detect the area of the tumor. However, tumor uptake on FDG-PET decreased markedly after the treatment in category II patients. In category III, both CT and FDG-PET detected the tumor, as in category I. Although there was no definite change in tumor size on CT, FDG-PET uptake was markedly reduced immediately after the treatment. Reduction in tumor size did not appear on CT until 2 months later. CONCLUSIONS: FDG-PET aids in analysis of the effectiveness of chemotherapy and/or radiotherapy.
BACKGROUND: This study evaluated the usefulness of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose (FDG-PET) in monitoring the response to continuous arterial infusion chemotherapy (CAI) combined with external radiation therapy (ERT) for unresectable pancreatic carcinomas. METHODS: Ten patients with unresectable pancreatic cancer were enrolled in this study. Computed tomography (CT) and FDG-PET were done before and after CAI (5-fluorouracil [FU], 500 mg/body per day) combined with ERT (50.4 Gy total dose). Tumor regression was evaluated by standardized uptake value (SUV) with FDG-PET, tumor size on CT, and changes in blood levels of carbohydrate antigen (CA) 19-9. The three methods of evaluation were compared. RESULTS: The ten patients were classified in three categories. In category I, tumor changes evident on CT and FDG-PET were consistent. In category II, CT could not accurately detect the area of the tumor. However, tumor uptake on FDG-PET decreased markedly after the treatment in category II patients. In category III, both CT and FDG-PET detected the tumor, as in category I. Although there was no definite change in tumor size on CT, FDG-PET uptake was markedly reduced immediately after the treatment. Reduction in tumor size did not appear on CT until 2 months later. CONCLUSIONS:FDG-PET aids in analysis of the effectiveness of chemotherapy and/or radiotherapy.
Authors: Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari Journal: World J Gastroenterol Date: 2011-02-21 Impact factor: 5.742
Authors: Dushyant V Sahani; Pietro A Bonaffini; Onofrio A Catalano; Alexander R Guimaraes; Michael A Blake Journal: Radiographics Date: 2012 Jul-Aug Impact factor: 5.333
Authors: Minsig Choi; Lance K Heilbrun; Raghu Venkatramanamoorthy; Jawana M Lawhorn-Crews; Mark M Zalupski; Anthony F Shields Journal: Am J Clin Oncol Date: 2010-06 Impact factor: 2.339
Authors: Derek J Erstad; Mozhdeh Sojoodi; Martin S Taylor; Veronica Clavijo Jordan; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs; Christian T Farrar; Andrea L Axtell; Nicholas J Rotile; Chloe Jones; Katherine A Graham-O'Regan; Diego S Ferreira; Theodoros Michelakos; Filippos Kontos; Akhil Chawla; Shen Li; Sarani Ghoshal; Yin-Ching Iris Chen; Gunisha Arora; Valerie Humblet; Vikram Deshpande; Motaz Qadan; Nabeel Bardeesy; Cristina R Ferrone; Michael Lanuti Journal: Clin Cancer Res Date: 2020-07-01 Impact factor: 12.531